P. Fallahi, S.M. Ferrari, G. Elia, F. Ragusa, S.R. Paparo, S. Camastra, V. Mazzi, M. Miccoli, S. Benvenga, A. Antonelli, Therapy of endocrine disease: endocrine-metabolic effects of treatment with multikinase inhibitors. Eur J Endocrinol 184(1), R29–R40 (2021). https://doi.org/10.1530/EJE-20-0683

Article  PubMed  CAS  Google Scholar 

M.E. Cabanillas, M.A. Habra, Lenvatinib: Role in thyroid cancer and other solid tumors. Cancer Treat Rev 42, 47–55 (2016). https://doi.org/10.1016/j.ctrv.2015.11.003

Article  PubMed  CAS  Google Scholar 

M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. de las Heras, J. Zhu, S.I. Sherman, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372(7), 621–630 (2015). https://doi.org/10.1056/NEJMoa1406470

Article  PubMed  CAS  Google Scholar 

M.S. Brose, Y. Panaseykin, B. Konda, C. de la Fouchardiere, B.G.M. Hughes, A.G. Gianoukakis, Y. Joo Park, I. Romanov, M.K. Krzyzanowska, S. Leboulleux, T.A. Binder, C. Dutcus, R. Xie, M.H. Taylor, A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. J Clin Endocrinol Metab 107(3), 776–787 (2022). https://doi.org/10.1210/clinem/dgab731

Article  PubMed  Google Scholar 

S. Hamidi, A. Boucher, B. Lemieux, G. Rondeau, R. Lebœuf, L.G. Ste-Marie, X.K. Le, H. Mircescu, Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects. J Endocr Soc 6(6), bvac048 (2022). https://doi.org/10.1210/jendso/bvac048

Article  PubMed  PubMed Central  CAS  Google Scholar 

M.D. Aydemirli, E. Kapiteijn, K.R.M. Ferrier, P.B. Ottevanger, T.P. Links, A.N.A. van der Horst-Schrivers, K.E. Broekman, R.H.H. Groenwold, J. Zwaveling, Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data. Eur J Endocrinol 182(2), 131–138 (2020). https://doi.org/10.1530/EJE-19-0763

Article  PubMed  CAS  Google Scholar 

L.D. Locati, A. Piovesan, C. Durante, M. Bregni, M.G. Castagna, S. Zovato, M. Giusti, T. Ibrahim, E. Puxeddu, G. Fedele, G. Pellegriti, G. Rinaldi, D. Giuffrida, F. Verderame, F. Bertolini, C. Bergamini, A. Nervo, G. Grani, S. Rizzati, S. Morelli, I. Puliafito, R. Elisei, Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur J Cancer 118, 35–40 (2019). https://doi.org/10.1016/j.ejca.2019.05.031

Article  PubMed  CAS  Google Scholar 

A. Berdelou, I. Borget, Y. Godbert, T. Nguyen, M.E. Garcia, C.N. Chougnet, A. Ferru, C. Buffet, O. Chabre, O. Huillard, S. Leboulleux, M. Schlumberger, Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice. Thyroid 28(1), 72–78 (2018). https://doi.org/10.1089/thy.2017.0205

Article  PubMed  CAS  Google Scholar 

M. Tahara, H. Takami, Y. Ito, K. Sugino, S. Takahashi, H. Takeyama, H. Tsutsui, H. Hara, A. Mitsuma, H. Yamashita, T. Okamoto, I. Sugitani, Y. Ohashi, T. Imai, Cohort study exploring the effect of lenvatinib on differentiated thyroid cancer. Endocr J 65(11), 1071–1074 (2018). https://doi.org/10.1507/endocrj.EJ18-0261

Article  PubMed  CAS  Google Scholar 

M. Tahara, H. Takami, Y. Ito, T. Okamoto, I. Sugitani, K. Sugino, S. Takahashi, H. Takeyama, H. Tsutsui, H. Hara, A. Mitsuma, H. Yamashita, Y. Ohashi, T. Imai, A Prospective Cohort Study Exploring the Effect of Lenvatinib Planned Drug Holidays in Treatment of Differentiated Thyroid Cancer. Thyroid 34(5), 566–574 (2024). https://doi.org/10.1089/thy.2023.0553

Article  PubMed  CAS  Google Scholar 

Surveillance Research Program, National Cancer Institute SEER*Stat software (Version 8.4.3 January 18, 2024; Last accessed 10 June 2024), seer.cancer.gov/seerstat

J. Wassermann, M.O. Bernier, J.P. Spano, C. Lepoutre-Lussey, C. Buffet, J.M. Simon, F. Ménégaux, F. Tissier, M. Leban, L. Leenhardt, Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas. Oncologist 21(1), 50–58 (2016). https://doi.org/10.1634/theoncologist.2015-0107

Article  PubMed  CAS  Google Scholar 

C. Colombo, S. De Leo, M. Trevisan, N. Giancola, A. Scaltrito, L. Fugazzola, Daily Management of Patients on Multikinase Inhibitors’ Treatment. Front Oncol 12, 903532 (2022). https://doi.org/10.3389/fonc.2022.903532

Article  PubMed  PubMed Central  CAS  Google Scholar 

Y. Koizumi, M. Hirooka, A. Hiraoka, H. Ochi, T. Tanaka, A. Yukimoto, Y. Imai, T. Watanabe, O. Yoshida, T. Miyake, B. Matsuura, K. Michitaka, K. Joko, M. Abe, Y. Hiasa, Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma. Endocr J 66(9), 787–792 (2019). https://doi.org/10.1507/endocrj.EJ19-0140

Article  PubMed  CAS  Google Scholar 

E. Acitelli, C. Maiorca, G. Grani, M. Maranghi, Metabolic adverse events of multitarget kinase inhibitors: a systematic review. Endocrine 81(1), 16–29 (2023). https://doi.org/10.1007/s12020-023-03362-2

Article  PubMed  PubMed Central  CAS  Google Scholar 

A.R. Lyon, T. López-Fernández, L.S. Couch et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J 43(41), 4229–4361 (2022). https://doi.org/10.1093/eurheartj/ehac244

Article  PubMed  Google Scholar 

M. Tuttle, L.F. Morris, B. Haugen, J. Shah, J.A. Sosa, E. Rohren, R.M. Subramaniam, J.L. Hunt, N.D. Perrier, Thyroid-differentiated and anaplastic carcinoma (Chapter 73). In AJCC Cancer Staging Manual, 8th ed. ed. by MB Amin, SB Edge, F Greene, D Byrd, RK Brookland, MK Washington, CC Compton, KR Hess, DC Sullivan, JM Jessup, et al. (Springer International Publishing, New York, NY, USA, 2017)

SCORE2 working group and ESC Cardiovascular risk collaboration, SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 42(25), 2439–2454 (2021). https://doi.org/10.1093/eurheartj/ehab309

Article  CAS  Google Scholar 

SCORE2-OP working group and ESC Cardiovascular risk collaboration, SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J 42(25), 2455–2467 (2021). https://doi.org/10.1093/eurheartj/ehab312

Article  Google Scholar 

Australian Guideline for assessing and managing cardiovascular disease risk. National Heart Foundation of Australia (Heart Foundation). Available from: https://www.cvdcheck.org.au/calculator (Accessed 10 Jul 2024)

E. Loukinova, S. Ranganathan, S. Kuznetsov, N. Gorlatova, M.M. Migliorini, D. Loukinov, P.G. Ulery, I. Mikhailenko, D.A. Lawrence, D.K. Strickland, Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function betwenn LRP and the PDGF. J Biol Chem 277(18), 15499–15506 (2002). https://doi.org/10.1074/jbc.M200427200

Article  PubMed  CAS  Google Scholar 

P. Boucher, M. Gotthardt, LRP and PDGF signaling: a pathway to atherosclerosis. Trends Cardiovasc Med 14(2), 55–60 (2004). https://doi.org/10.1016/j.tcm.2003.12.001

Article  PubMed  CAS  Google Scholar 

D.R. Shah, R.R. Shah, J. Morganroth, Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf 36(6), 413–426 (2013). https://doi.org/10.1007/s40264-013-0050-x

Article  PubMed  CAS  Google Scholar 

Y. Zheng, F. Wang, G. Wu, L. Zhang, Y. Wang, Z. Wang, P. Chen, Q. Wang, J. Lu, Y. Wang, P. Li, J. Wang, X. Lu, J. Yuan, The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China. Medicine 94(49), e2222 (2015). https://doi.org/10.1097/MD.0000000000002222

Article  PubMed  PubMed Central  CAS  Google Scholar 

K. Hokkanen, A. Tirronen, S. Ylä-Herttuala, Intestinal lymphatic vessels and their role in chylomicron absorption and lipid homeostasis. Curr Opin Lipidol 30(5), 370–376 (2019). https://doi.org/10.1097/MOL.0000000000000626

Article  PubMed  CAS  Google Scholar 

Y. Zhou, X. Zhu, H. Wang, C. Duan, H. Cui, J. Shi, S. Shi, G. Yuan, Y. Hu, The Role of VEGF Family in Lipid Metabolism. Curr Pharm Biotechnol 24(2), 253–265 (2023). https://doi.org/10.2174/1389201023666220506105026

Article  PubMed  CAS  Google Scholar 

M. Curtarello, M. Tognon, C. Venturoli, M. Silic-Benussi, A. Grassi, M. Verza, S. Minuzzo, M. Pinazza, V. Brillo, G. Tosi, R. Ferrazza, G. Guella, E. Iorio, A. Godfroid, N.E. Sounni, A. Amadori, S. Indraccolo, Rewiring of Lipid Metabolism and Storage in Ovarian Cancer Cells after Anti-VEGF Therapy. Cells 8(12), 1601 (2019). https://doi.org/10.3390/cells8121601

Article  PubMed  PubMed Central  CAS  Google Scholar